Sector News

Medtronic seeks EU approval for $43 billion Covidien deal

October 14, 2014
Life sciences
(Reuters) – U.S. medical equipment maker Medtronic (MDT.N) has asked European Union antitrust regulators to approve its proposed $43 billion (26.73 billion pounds) purchase of Irish peer Covidien Plc (COV.N), the European Commission said on Monday.
 
The acquisition, which will put Medtronic on about the same footing as industry leader Johnson & Johnson (JNJ.N), will reduce its overall global tax burden.
 
Medtronic however said it is not an inversion deal where U.S. companies acquire foreign rivals to move their tax domicile abroad, but rather a move to boost its medical technology strategy.
 
The EU competition authority has set a Nov. 14 deadline for its decision. It can either clear the deal unconditionally or ask for concessions to allay possible antitrust concerns or open an in-depth investigation.
 
Analysts said the disparate businesses of the two companies should not trigger any significant regulatory worries.
 
(Reporting by Foo Yun Chee; editing by Susan Thomas)

Related News

September 22, 2020

GSK’s Zejula and AZ’s Lynparza leap toward broader EU approval

Life sciences

GlaxoSmithKline’s Zejula and AstraZeneca’s Lynparza have both moved towards EU approval in new indications after receiving positive opinions from the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human […]

September 22, 2020

Roche acquires Irish biotech firm Inflazome

Life sciences

Swiss pharma company Roche is set to acquire Irish biotech firm Inflazome for an upfront payment of $449m (€380m). In addition to the upfront payment, Inflazome is also eligible to […]

September 18, 2020

Eli Lilly, Amgen join forces to scale production of COVID-19 antibody cocktails

Life sciences

Months of fervid research have whittled away most potential options to treat patients with COVID-19, a group of antibody cocktails still hold promise. Eli Lilly believes so strongly in its contender that it’s […]